This week brought a sweep of moves that collectively signal where MedTech is headed — and what it’s leaving behind. Merit Medical made a $140 million bet on breast cancer localization with its acquisition of View Point Medical. Abbott’s TriClip posted the strongest tricuspid repair data yet in the TRI-FR trial, cutting heart failure hospitalizations by 43%. Restore Robotics picked up its fourth FDA clearance to remanufacture da Vinci instruments — a direct shot at Intuitive Surgical’s per-procedure economics. Meanwhile, the industry’s biggest players are voluntarily breaking themselves apart: BD completed its life sciences spin-off, Medtronic’s MiniMed began trading as an independent company on Nasdaq, and the FTC’s new Healthcare Task Force is already reshaping what’s possible in device M&A. The era of the diversified MedTech conglomerate is unwinding in real time. Welcome to Issue #11 of The MedTech Minute.
Top Stories
Story 01
For years, tumor localization has been an afterthought in surgical oncology — a low-profile procedural step overshadowed by higher-profile therapeutic devices. But the shift toward tissue-sparing lumpectomies and image-guided procedures is turning localization technology into a competitive battleground. Merit Medical just made the most significant move in that space this year. (Source: Business Wire, April 1, 2026)
Merit Medical Systems acquired View Point Medical for approximately $140 million — $90 million cash at closing, with two deferred payments of $25 million each over the next two years. View Point’s flagship product is the OneMark Detection Imaging System, an FDA-cleared platform combining a surgical detection console with ultrasound-enhanced tissue markers for breast cancer localization.
Why It Matters: Merit already owns SCOUT, one of the leading radar-based localization platforms in breast surgery. Adding View Point’s OneMark system gives Merit two complementary technologies — radar-based and ultrasound-enhanced — that cover different clinical workflows and surgeon preferences. The oncology localization market is expected to reach $1.2 billion by 2028. Merit just consolidated the two strongest non-wire technologies under one roof.
M&A
Oncology
FDA Cleared
Story 02
Tricuspid regurgitation — a leaky valve on the right side of the heart — affects roughly 1.6 million Americans with severe disease. Until recently, most patients were managed with medications alone because open-heart surgery carried prohibitive risk. Transcatheter tricuspid repair was supposed to change that, but early trials were muddied by crossover — patients in the control arm switching to the device before the study concluded. (Source: Cardiac Interventions Today; presented at ACC 2026, New Orleans)
TRI-FR changed the design. In this French multicenter randomized trial, 300 patients with severe symptomatic tricuspid regurgitation were assigned to transcatheter tricuspid edge-to-edge repair (T-TEER) with the TriClip system (Abbott) plus medical therapy, or medical therapy alone — with no crossover permitted. At 2 years, the primary composite endpoint occurred in 19.7% of TriClip patients versus 34.5% in the medical therapy group, driven primarily by a significant reduction in heart failure hospitalizations.
Why It Matters: This is the cleanest comparative data the tricuspid repair field has produced. By blocking crossover, TRI-FR removed the contamination that weakened prior studies and provided a genuine two-year look at how T-TEER performs against medication alone. For Abbott, the data strengthens the TriClip reimbursement case and positions the device for broader guideline inclusion. For the structural heart field, it validates that the transcatheter approach to the “forgotten valve” has durable, measurable clinical benefit.
Clinical Trial
Structural Heart
ACC 2026
Story 03
Intuitive Surgical generates roughly 57% of its revenue not from selling da Vinci robotic systems, but from the instruments and accessories that must be replaced after a set number of uses — typically 10 procedures. This per-procedure consumable model has been one of the most profitable recurring revenue streams in all of MedTech. It has also been, until recently, entirely unchallenged. (Source: PR Newswire, March 31, 2026; MedTech Dive)
Restore Robotics announced FDA 510(k) clearance for two additional da Vinci Xi instruments — the permanent cautery hook and permanent cautery spatula. The company now holds four total clearances for remanufactured Intuitive Surgical instruments, all distributed through its partnership with Encore Medical Device Repair. Notably, Intuitive itself has granted approval under its contracts for Restore to remanufacture any EndoWrist instrument that falls within the scope of an FDA clearance.
Why It Matters: Four clearances in and Restore is still expanding. Each cleared instrument opens another line item in hospital procurement budgets where the remanufactured alternative can compete on price while maintaining FDA-level quality standards. Intuitive has continued to outperform Wall Street forecasts despite this competition — but the trajectory matters more than the current quarter. If Restore keeps adding high-utilization instruments, the economics of robotic surgery shift toward the hospital and away from the OEM. The razor-blade model isn’t broken yet. But the blade just got a competitor.
FDA Clearance
Surgical Robotics
Market Disruption
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG ★ | Intuitive Surgical | $438.60 | ▼ 4.2% |
| SYK | Stryker | $385.20 | ▼ 0.5% |
| BDX | BD (Becton Dickinson) | $231.50 | ▲ 1.4% |
| JNJ | Johnson & Johnson | $157.20 | ▼ 2.1% |
| ABT | Abbott | $157.10 | ▲ 3.5% |
| ZBH | Zimmer Biomet | $106.40 | ▼ 0.9% |
| BSX | Boston Scientific | $98.50 | ▼ 3.8% |
| GEHC | GE HealthCare | $98.00 | ▲ 1.9% |
| MDT | Medtronic | $91.90 | ▲ 2.8% |
| EW | Edwards Lifesciences | $75.90 | ▲ 0.6% |
★ Biggest Mover: ISRG fell 4.2% as Restore Robotics expanded its remanufactured da Vinci footprint, pressuring Intuitive's install-base dominance. ABT rose 3.5% on strong TriClip TRI-FR data at ACC 2026. MDT gained on MiniMed IPO momentum and Hugo RAS scaling. Sorted by stock price, highest to lowest. Data shown for illustrative purposes. Prices reflect approximate close, week of April 4, 2026.
Industry Shift
Shift 01
For over a decade, every FDA-approved TAVR device was designed for aortic stenosis — a narrowed, calcified valve. Aortic regurgitation, where the valve leaks, presented a fundamentally different engineering challenge: no calcification means no natural anchor point for the implant. A dedicated TAVR device for regurgitation remained an unmet need. (Source: TCTMD, March 18, 2026; Cardiovascular Business)
On March 18, JenaValve received FDA premarket approval for its Trilogy transcatheter heart valve system — the first and only TAVR device approved for symptomatic severe aortic regurgitation in the U.S. The approval was supported by the ALIGN-AR pivotal trial. But the path to this moment was anything but straightforward: Edwards Lifesciences agreed to acquire JenaValve for $945 million in 2024. The FTC sued to block the deal in August 2025, arguing it would eliminate competition in the TAVR-AR market. In January 2026, a federal court granted the injunction, and Edwards walked away. JenaValve proceeded independently — and got the approval two months later.
Why It Matters: JenaValve’s story is a case study in what happens when antitrust enforcement intersects with device innovation. The FTC argued that the acquisition would have killed head-to-head competition — Edwards had already acquired JC Medical, the only other company developing a TAVR-AR device. By blocking the deal, the FTC preserved an independent JenaValve that is now the sole holder of the first TAVR-AR indication in the U.S. For the broader MedTech M&A landscape, this signals that the FTC’s Healthcare Task Force (formed March 2026) is willing to challenge deals that consolidate competition at the innovation stage, not just in fully commercialized markets.
Regulatory
FDA Approval
Structural Heart
Deep Dive
The Great MedTech Unbundling: Why the Biggest Device Companies Are Breaking Themselves Apart
Something fundamental shifted in MedTech in early 2026. Two of the industry’s largest conglomerates — Becton Dickinson and Medtronic — executed landmark portfolio separations within weeks of each other. These aren’t divestitures of underperforming units. They’re strategic bets that the era of the diversified MedTech conglomerate is over — and that focused, pure-play companies will win the next decade.
- BD completed the spin-off of its Biosciences and Diagnostic Solutions business on February 9, 2026. The separated unit merged with Waters Corporation, generating $4 billion in cash proceeds for “New BD.” What remains is a leaner medical technology company focused on connected care, medication management, and interventional surgery — anchored by products like the Alaris infusion pump and the newly FDA-cleared Surgiphor antimicrobial irrigation system. BD ended 2025 with a 3.0x leverage ratio and targets 2.5x by late 2026. The 127-year-old conglomerate just became a pure-play.
- Medtronic completed a partial IPO of its MiniMed diabetes business on March 6, 2026. MiniMed Group (Nasdaq: MMED) began trading on the Nasdaq Global Select Market in what Medtronic called the second-largest MedTech IPO in history at $538 million. Medtronic retains roughly 90% of MiniMed and plans a full separation by end of 2026. The rationale: MiniMed’s consumer-tech insulin pump business operates on entirely different growth dynamics, R&D cycles, and investor expectations than Medtronic’s core surgical and cardiovascular portfolio. Keeping them together was costing both businesses valuation.
- The pattern is structural, not anecdotal. Johnson & Johnson is exploring separation of its orthopedic division. The FTC’s new Healthcare Task Force is scrutinizing portfolio acquisitions. Tariff pressures are forcing manufacturing reshoring that favors smaller, focused supply chains over sprawling global operations. The conglomerate premium that justified these portfolios — cross-selling across hospital systems, shared regulatory infrastructure, diversified revenue — is being repriced. Investors now reward focus, margin clarity, and pure-play narratives.
The bottom line: The MedTech conglomerate was built for a world where hospitals bought from a handful of vendors and diversification reduced risk. That world is ending. Hospitals now evaluate technologies on clinical evidence and outcomes data, not vendor breadth. Investors reward companies they can model cleanly. And regulators are increasingly hostile to portfolio acquisitions. BD and Medtronic read the landscape and moved first. The companies that wait — or resist — will find themselves valued at a conglomerate discount that only grows.
The Builder's Take
First-in-Indication Beats First-to-Market — The JenaValve Lesson
JenaValve didn’t try to out-execute Edwards Lifesciences in aortic stenosis, where Edwards owns roughly 60% of the TAVR market. It built the definitive device for an adjacent, underserved indication — aortic regurgitation — where no transcatheter solution existed. When the FTC blocked the acquisition, JenaValve’s indication-first strategy gave it the independence to succeed alone. Two months later, it held the only FDA-approved TAVR-AR device in the United States.
The lesson for MedTech builders: if you’re entering a category where one player dominates, don’t compete on their turf. Find the adjacent indication that nobody owns. Build the evidence around it. Own the label. The regulatory moat around a first-in-indication approval is deeper than any commercial head start a larger competitor can buy — especially when that competitor can’t close the acquisition.
JenaValve just demonstrated that first-in-indication can be more strategically valuable than first-to-market. In a world where the FTC is actively blocking roll-up strategies, building a device that creates a new regulatory category isn’t just smart science. It’s the best M&A defense money can’t buy.
Fun Fact & Trivia
🧠 Fun Fact — The First Surgical Robot Went Bankrupt
The first surgical robot wasn’t da Vinci — it was ROBODOC, developed in 1992 by Integrated Surgical Systems to mill bone surfaces during hip replacement surgery. The system was so far ahead of its time that it took over a decade for the orthopedic world to embrace robotic assistance. Integrated Surgical Systems eventually went bankrupt in 2005. Today, surgical robotics is a $7+ billion market and growing at double digits annually. One company — Intuitive Surgical — controls roughly 80% of it. That dominance is now facing its first serious challenge, not from a company building a rival robot, but from one rebuilding the instruments that go inside one.
MedTech Trivia
What approximate percentage of Intuitive Surgical’s total revenue comes from instruments and accessories rather than system sales — making it one of the most successful “razor-and-blade” models in all of MedTech?
👇 Scroll to the footer for the answer
MedTech Word Search
🧩 Find the Hidden MedTech Terms, Click to Highlight
TRICLIP
SIRPAD
MERIT
MINIMED
RESTORE
DAVINCI
Words hidden horizontally (→) and vertically (↓). Click letters to mark your finds.
Quick Question
Is the MedTech conglomerate era really over — or will focused pure-plays eventually re-bundle into the next generation of diversified companies? I’m curious whether you think BD and Medtronic’s spin-offs are a lasting structural shift or a cyclical swing. Hit reply, I read every response.
Sponsor
